SCHEMBL5201027

SCHEMBL5201027

N/C(=C/C(=O)O)c1ccccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.66
LMNA P02545 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
NAPRT Q6XQN6 1/20 0.57
P4HTM Q9NXG6 1/20 0.57
CES2 O00748 1/20 0.53
CES1 P23141 1/20 0.53
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 2/20 0.50
NPC1 O15118 3/20 0.49
PKM P14618 3/20 0.49
RAB9A P51151 3/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
MITF O75030 1/20 0.47
CDK5 Q00535 1/20 0.47
CDK5R1 Q15078 1/20 0.47
GSK3B P49841 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HDAC3 O15379 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14630074 1.00 MAPK1 (0.66) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL14630072 1.00 MAPK1 (0.66) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL28996723 0.87 MAPK1 (0.68) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL28178667 0.82 MAPK1 (0.54) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL29078777 0.79 MAPK1 (0.58) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL11837470 0.78 MAPK1 (0.57) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL11837475 0.78 MAPK1 (0.57) MAPK1LMNAL3MBTL1NAPRTP4HTM
Fumaric Acid SCHEMBL4354675 0.78 LMNA (0.57) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL11538095 0.78 LMNA (0.57) MAPK1LMNAL3MBTL1NAPRTP4HTM
SCHEMBL27330261 0.78 LMNA (0.57) MAPK1LMNAL3MBTL1NAPRTP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054924-A1 Novel piperidines as chemokine modulators (ccr) ASTRAZENECA AB (SE) 2007-03-08 US disclosed
EP-1713772-A1 NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) AstraZeneca AB (SE) 2006-10-25 EP disclosed
WO-2005073192-A1 NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) ASTRAZENECA AB (SE) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054924-A1 Novel piperidines as chemokine modulators (ccr) CCR3, CCR1, CCR4 MAPK1 1012/4885LMNA 4676/4885L3MBTL1 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.